Hypoxia, hypoxia-inducible transcription factors, and renal cancer
Context Renal cancer is a common urologic malignancy, and therapeutic options for
metastatic disease are limited. Most clear cell renal cell carcinomas (ccRCC) are associated …
metastatic disease are limited. Most clear cell renal cell carcinomas (ccRCC) are associated …
von Hippel-Lindau disease
Summary von Hippel-Lindau disease is a heritable multisystem cancer syndrome that is
associated with a germline mutation of the VHL tumour suppressor gene on the short arm of …
associated with a germline mutation of the VHL tumour suppressor gene on the short arm of …
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal …
RJ Motzer, MD Michaelson, BG Redman… - Journal of Clinical …, 2006 - ascopubs.org
Purpose Renal cell carcinoma (RCC) is characterized by loss of von Hippel Lindau tumor
suppressor gene activity, resulting in high expression of pro-angiogenic growth factors …
suppressor gene activity, resulting in high expression of pro-angiogenic growth factors …
Genomic profiling in renal cell carcinoma
The treatment landscape of metastatic renal cell carcinoma (RCC) has been revolutionized
over the past two decades, bringing forth an era in which more than a dozen therapeutic …
over the past two decades, bringing forth an era in which more than a dozen therapeutic …
Role of VHL Gene Mutation in Human Cancer
WY Kim, WG Kaelin - Journal of clinical oncology, 2004 - ascopubs.org
Germline inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene causes the
von Hippel-Lindau hereditary cancer syndrome, and somatic mutations of this gene have …
von Hippel-Lindau hereditary cancer syndrome, and somatic mutations of this gene have …
Sunitinib in patients with metastatic renal cell carcinoma
ContextCurrent treatment options for metastatic renal cell carcinoma (RCC) are limited and
there is a need to identify novel and effective therapies. Sunitinib malate is an oral …
there is a need to identify novel and effective therapies. Sunitinib malate is an oral …
von Hippel–Lindau disease
P Chittiboina, RR Lonser - Handbook of clinical neurology, 2015 - Elsevier
Abstract von Hippel–Lindau (VHL) disease is an inheritable condition with an incidence of 1
in 36 000 live births. Individuals with VHL develop benign and malignant tumors including …
in 36 000 live births. Individuals with VHL develop benign and malignant tumors including …
[HTML][HTML] HIF-α effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma
JD Gordan, P Lal, VR Dondeti, R Letrero, KN Parekh… - Cancer cell, 2008 - cell.com
Summary von Hippel-Lindau (VHL) tumor suppressor loss results in hypoxia-inducible factor
alpha (HIF-α) stabilization and occurs in 70% of sporadic clear cell renal carcinomas …
alpha (HIF-α) stabilization and occurs in 70% of sporadic clear cell renal carcinomas …
Biology and clinical development of vascular endothelial growth factor–targeted therapy in renal cell carcinoma
BI Rini, EJ Small - Journal of Clinical Oncology, 2005 - ascopubs.org
Purpose To review the biology of renal cell carcinoma (RCC) leading to vascular endothelial
growth factor (VEGF) overexpression and the clinical results of VEGF blockade in metastatic …
growth factor (VEGF) overexpression and the clinical results of VEGF blockade in metastatic …
Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic
G Ranieri, R Patruno, E Ruggieri… - Current medicinal …, 2006 - ingentaconnect.com
Angiogenesis is important in the growth and progression of solid tumours. The main pro-
angiogenic factor, namely vascular endothelial growth factor (VEGF), also known as …
angiogenic factor, namely vascular endothelial growth factor (VEGF), also known as …